减肥降低了肥胖的绝经后妇女的C反应性蛋白水平
André Tchernof1, Amy Nolan, Cynthia K Sites
1Department of Medicine, College of Medicine, University of Vermont, Burlington.
Circulation
|February 6, 2002
概括
减肥显著降低了肥胖的绝经后妇女的C反应性蛋白 (CRP) 水平. 这种降低CRP,炎症的标志物,可能有助于减肥的心血管益处.
科学领域:
- 心血管疾病研究研究
- 肥胖和代谢研究 肥胖和代谢研究
- 炎症生物标志物 炎症生物标志物
背景情况:
- 反应性C蛋白 (CRP) 与心血管疾病风险有关,并与体重和肥胖度有关.
- 该研究调查了体重减轻是否可以降低肥胖的绝经后妇女的血CRP水平.
研究的目的:
- 为了确定减肥是否降低了肥胖的绝经后妇女的血CRP水平.
- 探索脂肪和CRP水平之间的关系.
主要方法:
- 对61名肥胖的绝经后妇女进行横截面分析,以评估CRP与身体脂肪的相关性.
- 干预研究涉及25名接受减肥方案的女性.
- 测量包括双X射线吸收度,CT扫描和高胰岛素-高血糖.
主要成果:
- 血CRP水平与全身脂肪和腹内脂肪区域正相关.
- 在CRP和甘油三水平和葡萄糖处置之间也发现了显著的相关性.
- 体重减轻 (平均15.6%) 显著降低了血CRP水平32.3% (P<0.0001).
结论:
- 肥胖是肥胖的绝经后妇女血CRP的重要预测因素.
- 卡路里限制引起的体重减轻有效降低了血CRP水平.
- 减肥可能是降低CRP和调节心脏保护作用的关键干预措施.
相关概念视频
Obesity
1.5K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
Menopause
5.0K
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
5.0K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
440
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
440
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
324
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
324
Atherosclerosis III: Management
741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741
Chronic Kidney Disease III: Interprofessional Care
679
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
679


